Publications from OUS - Lymphoma biology group (Myklebust)

280 publications found

Publications 2024

1. Bai B, Wise JF, Vodák D, Nakken S, Sharma A, Blaker YN, Brodtkorb M, Hilden V, Trøen G, Ren W, Lorenz S, Lawrence MS, Myklebost O, Kimby E, Pan-Hammarström Q, Steen CB, Meza-Zepeda LA, Beiske K, Smeland EB, Hovig E, Lingjærde OC, Holte H, Myklebust JH (2024)
   Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma
   Blood Cancer J, 14 (1), 147
   DOI 10.1038/s41408-024-01124-5, PubMed 39191762
2. Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
   Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
   NPJ Breast Cancer, 10 (1), 30
   DOI 10.1038/s41523-024-00638-2, PubMed 38653982
3. Meriranta L, Sorri S, Huse K, Liu X, Spasevska I, Zafar S, Chowdhury I, Dufva O, Sahlberg E, Tandarić L, Karjalainen-Lindsberg ML, Hyytiäinen M, Varjosalo M, Myklebust JH, Leppä S (2024)
   Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma
   Blood Cancer Discov, 5 (5), 331-352
   DOI 10.1158/2643-3230.BCD-23-0182, PubMed 38630892
4. Otterlei Fjørtoft M, Huse K, Rye IH (2024)
   The Tumor Immune Microenvironment in Breast Cancer Progression
   Acta Oncol, 63, 359-367
   DOI 10.2340/1651-226X.2024.33008, PubMed 38779867

Publications 2023

1. Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S (2023)
   Efficient chimeric antigen receptor targeting of a central epitope of CD22
   J Biol Chem, 299 (7), 104883
   DOI 10.1016/j.jbc.2023.104883, PubMed 37269947
2. Isaksen KT, Galleberg R, Mastroianni MA, Rinde M, Rusten LS, Barzenje D, Ramslien F, Fluge O, Slaaen M, Meyer P, Liestol K, Smeland EB, Lingjarde OC, Holte H, Brodtkorb M (2023)
   The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
   Haematologica, 108 (9), 2454-2466
   DOI 10.3324/haematol.2022.282289, PubMed 36861406
3. Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K et al. (2023)
   Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
   Blood Adv, 7 (23), 7216-7230
   DOI 10.1182/bloodadvances.2023010158, PubMed 37695745
4. Vahid MR, Brown EL, Steen CB, Zhang W, Jeon HS, Kang M, Gentles AJ, Newman AM (2023)
   High-resolution alignment of single-cell and spatial transcriptomes with CytoSPACE
   Nat Biotechnol, 41 (11), 1543-1548
   DOI 10.1038/s41587-023-01697-9, PubMed 36879008

Publications 2022

1. Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, Myklebust JH (2022)
   Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression
   J Immunol, 209 (10), 2042-2053
   DOI 10.4049/jimmunol.2200144, PubMed 36426942

Publications 2021

1. Isaksen KT, Mastroianni MA, Rinde M, Rusten LS, Barzenje DA, Ramslien LF, Slaaen M, Jerm MB, Smeland EB, Rostoft S, Liestøl K, Brodtkorb M, Holte H (2021)
   A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
   Blood Adv, 5 (22), 4771-4782
   DOI 10.1182/bloodadvances.2021004777, PubMed 34543384
2. Langenbucher A, Bowen D, Sakhtemani R, Bournique E, Wise JF, Zou L, Bhagwat AS, Buisson R, Lawrence MS (2021)
   An extended APOBEC3A mutation signature in cancer
   Nat Commun, 12 (1), 1602
   DOI 10.1038/s41467-021-21891-0, PubMed 33707442
3. Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
   Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
   Sci Rep, 11 (1), 6317
   DOI 10.1038/s41598-021-85613-8, PubMed 33737576
4. Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
   Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
   Mol Oncol, 16 (1), 88-103
   DOI 10.1002/1878-0261.13047, PubMed 34165864
5. Sanjiv K, Calderón-Montaño JM, Pham TM, Erkers T, Tsuber V, Almlöf I, Höglund A, Heshmati Y, Seashore-Ludlow B, Nagesh Danda A, Gad H, Wiita E, Göktürk C, Rasti A, Friedrich S, Centio A, Estruch M, Våtsveen TK, Struyf N, Visnes T, Scobie M, Koolmeister T, Henriksson M, Wallner O, Sandvall T et al. (2021)
   MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia
   Cancer Res, 81 (22), 5733-5744
   DOI 10.1158/0008-5472.CAN-21-0061, PubMed 34593524
6. Spasevska I, Myklebust JH (2021)
   What It Takes to Transform a T Cell
   Cancer Res, 81 (12), 3160-3161
   DOI 10.1158/0008-5472.CAN-21-0784, PubMed 34224376
7. Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, Kurtz DM, Liu CL, Khameneh F, Advani RH, Natkunam Y, Myklebust JH, Diehn M, Gentles AJ, Newman AM, Alizadeh AA (2021)
   The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
   Cancer Cell, 39 (10), 1422-1437.e10
   DOI 10.1016/j.ccell.2021.08.011, PubMed 34597589

Publications 2020

1. Bai B, Myklebust JH, Wälchli S (2020)
   Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology
   Methods Mol Biol, 2115, 445-454
   DOI 10.1007/978-1-0716-0290-4_25, PubMed 32006416
2. Isaksen KT, Beiske K, Smeland EB, Jørgensen J, Brodtkorb M, Myklebust JH, Jerkeman M, Meriranta L, Karjalainen-Lindsberg ML, Leppä S, Scott DW, Holte H, Blaker YN (2020)
   The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
   EJHaem, 2 (1), 104-108
   DOI 10.1002/jha2.109, PubMed 35846101
3. Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
   Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
   Br J Haematol, 189 (4), 661-671
   DOI 10.1111/bjh.16425, PubMed 32017050
4. Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
   Combinatorial CAR design improves target restriction
   J Biol Chem, 296, 100116
   DOI 10.1074/jbc.RA120.016234, PubMed 33234592
5. Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL (2020)
   Tuning the Antigen Density Requirement for CAR T-cell Activity
   Cancer Discov, 10 (5), 702-723
   DOI 10.1158/2159-8290.CD-19-0945, PubMed 32193224
6. Rein ID, Notø HØ, Bostad M, Huse K, Stokke T (2020)
   Cell Cycle Analysis and Relevance for Single-Cell Gating in Mass Cytometry
   Cytometry A, 97 (8), 832-844
   DOI 10.1002/cyto.a.23960, PubMed 31943748
7. Sonnet F, Namork E, Stylianou E, Gaare-Olstad I, Huse K, Andorf S, Mjaaland S, Dirven H, Nygaard U (2020)
   Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food
   BMC Immunol, 21 (1), 43
   DOI 10.1186/s12865-020-00373-w, PubMed 32698761
8. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
   Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
   Blood Adv, 4 (9), 1859-1866
   DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

1. Huse K (2019)
   Expanding the Clinical Cytometry Toolbox-Receptor Occupancy by Mass Cytometry
   Cytometry A, 95 (10), 1046-1048
   DOI 10.1002/cyto.a.23784, PubMed 31046178
2. Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM (2019)
   Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response
   Cytometry A, 95 (4), 442-449
   DOI 10.1002/cyto.a.23737, PubMed 30838773
3. Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
   TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
   Cancer Immunol Res, 7 (3), 355-362
   DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053
4. Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
   Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
   Blood Adv, 3 (8), 1230-1243
   DOI 10.1182/bloodadvances.2018029678, PubMed 30979721
5. Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
   NK cells specifically TCR-dressed to kill cancer cells
   EBioMedicine, 40, 106-117
   DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853
6. Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
   A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
   Haematologica, 104 (10), e460-e464
   DOI 10.3324/haematol.2018.209080, PubMed 30846496
7. Wise JF, Lawrence MS (2019)
   Huge whole-genome study of human metastatic cancers
   Nature, 575 (7781), 60-61
   DOI 10.1038/d41586-019-03123-0, PubMed 31690848

Publications 2018

1. Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
   The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
   Br J Haematol, 183 (2), 225-234
   DOI 10.1111/bjh.15518, PubMed 30080252
2. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018)
   Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
   Blood, 132 (22), 2401-2405
   DOI 10.1182/blood-2018-05-851154, PubMed 30257882
3. Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
   Sample-Index Misassignment Impacts Tumour Exome Sequencing
   Sci Rep, 8 (1), 5307
   DOI 10.1038/s41598-018-23563-4, PubMed 29593270
4. Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
   Artesunate shows potent anti-tumor activity in B-cell lymphoma
   J Hematol Oncol, 11 (1), 23
   DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

1. Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
   BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
   PLoS One, 12 (5), e0177188
   DOI 10.1371/journal.pone.0177188, PubMed 28489883
2. Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
   Human c-SRC kinase (CSK) overexpression makes T cells dummy
   Cancer Immunol Immunother, 67 (4), 525-536
   DOI 10.1007/s00262-017-2105-9, PubMed 29248956
3. Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
   T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
   Oncoimmunology, 6 (4), e1302631
   DOI 10.1080/2162402X.2017.1302631, PubMed 28507809
4. Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
   T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
   Clin Cancer Res, 24 (4), 870-881
   DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528
5. Koksal H, Walchli S (2017)
   Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?
   Transl. Cancer Res., 6 3, S622-S624
   DOI 10.21037/tcr.2017.05.25
6. Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
   New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
   J Clin Oncol, 35 (15), 1668-1677
   DOI 10.1200/JCO.2016.70.7901, PubMed 28291392
7. Taraldsrud E, Fevang B, Jørgensen SF, Moltu K, Hilden V, Taskén K, Aukrust P, Myklebust JH, Olweus J (2017)
   Defective IL-4 signaling in T cells defines severe common variable immunodeficiency
   J Autoimmun, 81, 110-119
   DOI 10.1016/j.jaut.2017.04.004, PubMed 28476239
8. Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
   A TCR-based Chimeric Antigen Receptor
   Sci Rep, 7 (1), 10713
   DOI 10.1038/s41598-017-11126-y, PubMed 28878363
9. Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
   Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
   Cytometry B Clin Cytom, 92 (1), 79-87
   DOI 10.1002/cyto.b.21498, PubMed 27933753

Publications 2016

1. Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M (2016)
   Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants
   Mol Ther, 24 (9), 1675-85
   DOI 10.1038/mt.2016.134, PubMed 27377043
2. Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
   The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
   Br J Haematol, 175 (1), 102-14
   DOI 10.1111/bjh.14201, PubMed 27341313
3. Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK (2016)
   Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
   Immunology, 149 (1), 62-73
   DOI 10.1111/imm.12629, PubMed 27278254
4. Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
   T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
   Oncoimmunology, 5 (12), e1249090
   DOI 10.1080/2162402X.2016.1249090, PubMed 28123886
5. Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
   Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
   Oncoimmunology, 5 (5), e1138199
   DOI 10.1080/2162402X.2016.1138199, PubMed 27467957
6. Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R (2016)
   Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
   Blood, 129 (6), 759-770
   DOI 10.1182/blood-2016-05-718494, PubMed 28011673
7. Taraldsrud E, Aukrust P, Jørgensen S, Lingjærde OC, Olweus J, Myklebust JH, Fevang B (2016)
   Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency
   Clin Immunol, 175, 69-74
   DOI 10.1016/j.clim.2016.11.014, PubMed 27919819

Publications 2015

1. Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
   Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
   Histopathology, 67 (1), 62-9
   DOI 10.1111/his.12624, PubMed 25431344
2. Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A (2015)
   Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
   Biol Blood Marrow Transplant, 21 (5), 840-7
   DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789
3. Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T (2015)
   New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX
   Cell Cycle, 14 (20), 3261-9
   DOI 10.1080/15384101.2015.1087617, PubMed 26317799
4. Oksvold MP (2015)
   Incidence of Data Duplications in a Randomly Selected Pool of Life Science Publications
   Sci Eng Ethics, 22 (2), 487-96
   DOI 10.1007/s11948-015-9668-7, PubMed 26065681
5. Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY (2015)
   The targeting of human and mouse B lymphocytes by dasatinib
   Exp Hematol, 43 (5), 352-363.e4
   DOI 10.1016/j.exphem.2015.01.008, PubMed 25641047
6. Oksvold MP, Neurauter A, Pedersen KW (2015)
   Magnetic bead-based isolation of exosomes
   Methods Mol Biol, 1218, 465-81
   DOI 10.1007/978-1-4939-1538-5_27, PubMed 25319668
7. Polikowsky HG, Wogsland CE, Diggins KE, Huse K, Irish JM (2015)
   Cutting Edge: Redox Signaling Hypersensitivity Distinguishes Human Germinal Center B Cells
   J Immunol, 195 (4), 1364-1367
   DOI 10.4049/jimmunol.1500904, PubMed 26157177
8. Tadesse FG, Mensali N, Fallang LE, Walseng E, Yang W, Olweus J, Wälchli S (2015)
   Unpredicted phenotypes of two mutants of the TcR DMF5
   J Immunol Methods, 425, 37-44
   DOI 10.1016/j.jim.2015.06.006, PubMed 26079729
9. Theodossiou TA, Wälchli S, Olsen CE, Skarpen E, Berg K (2015)
   Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity
   ACS Chem Biol, 11 (1), 251-62
   DOI 10.1021/acschembio.5b00734, PubMed 26569462
10. Walseng E, Wälchli S, Fallang LE, Yang W, Vefferstad A, Areffard A, Olweus J (2015)
    Soluble T-cell receptors produced in human cells for targeted delivery
    PLoS One, 10 (4), e0119559
    DOI 10.1371/journal.pone.0119559, PubMed 25875651

Publications 2014

1. Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
   A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
   PLoS One, 9 (9), e104249
   DOI 10.1371/journal.pone.0104249, PubMed 25226156
2. Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
   High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
   Leuk Lymphoma, 55 (10), 2319-27
   DOI 10.3109/10428194.2013.871632, PubMed 24432894
3. Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
   Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
   Leuk Lymphoma, 56 (6), 1742-9
   DOI 10.3109/10428194.2014.970550, PubMed 25284491
4. Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW (2014)
   Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells
   Clin Ther, 36 (6), 847-862.e1
   DOI 10.1016/j.clinthera.2014.05.010, PubMed 24952935
5. Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
   Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
   Haematologica, 100 (2), 238-45
   DOI 10.3324/haematol.2014.113472, PubMed 25381134
6. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM (2014)
   Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
   Blood, 123 (8), 1214-7
   DOI 10.1182/blood-2013-11-536433, PubMed 24398326
7. Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A et al. (2014)
   Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms
   Cancer Discov, 4 (4), 480-93
   DOI 10.1158/2159-8290.CD-13-0915, PubMed 24491438

Publications 2013

1. Arita A, McFarland DC, Myklebust JH, Parekh S, Petersen B, Gabrilove J, Brody JD (2013)
   Signaling pathways in lymphoma: pathogenesis and therapeutic targets
   Future Oncol, 9 (10), 1549-71
   DOI 10.2217/fon.13.113, PubMed 24106904
2. Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
   Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
   PLoS One, 8 (11), e79602
   DOI 10.1371/journal.pone.0079602, PubMed 24260260
3. Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
   Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
   Epigenetics, 9 (3), 428-36
   DOI 10.4161/epi.27554, PubMed 24362313
4. Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB (2013)
   Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
   Blood, 123 (7), 1051-4
   DOI 10.1182/blood-2013-07-512392, PubMed 24357726
5. Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA et al. (2013)
   EZH2 mutations are frequent and represent an early event in follicular lymphoma
   Blood, 122 (18), 3165-8
   DOI 10.1182/blood-2013-04-496893, PubMed 24052547
6. Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H (2013)
   Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome
   Eur J Haematol, 91 (4), 332-8
   DOI 10.1111/ejh.12171, PubMed 23859481
7. Kumari S, Wälchli S, Fallang LE, Yang W, Lund-Johansen F, Schumacher TN, Olweus J (2013)
   Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes
   Proc Natl Acad Sci U S A, 111 (1), 403-8
   DOI 10.1073/pnas.1306549111, PubMed 24344295
8. Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2013)
   Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
   Leuk Lymphoma, 55 (2), 288-95
   DOI 10.3109/10428194.2013.802778, PubMed 23662992
9. Wälchli S, Kumari S, Fallang LE, Sand KM, Yang W, Landsverk OJ, Bakke O, Olweus J, Gregers TF (2013)
   Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation
   Eur J Immunol, 44 (3), 774-84
   DOI 10.1002/eji.201343671, PubMed 24293164
10. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
    Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
    Leuk Lymphoma, 54 (10), 2205-14
    DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

1. Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP (2012)
   SARA is dispensable for functional TGF-β signaling
   FEBS Lett, 586 (19), 3367-72
   DOI 10.1016/j.febslet.2012.07.027, PubMed 22819827
2. Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A (2012)
   Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
   BMC Cancer, 12, 478
   DOI 10.1186/1471-2407-12-478, PubMed 23072591
3. Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012)
   Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
   Br J Haematol, 159 (5), 604-8
   DOI 10.1111/bjh.12073, PubMed 23043253
4. Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH (2012)
   Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma
   PLoS One, 7 (10), e46117
   DOI 10.1371/journal.pone.0046117, PubMed 23049692
5. Oksvold MP, Pedersen NM, Forfang L, Smeland EB (2012)
   Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling
   FEBS Lett, 586 (20), 3575-81
   DOI 10.1016/j.febslet.2012.08.022, PubMed 22971756
6. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES et al. (2012)
   Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
   Nature, 490 (7418), 116-20
   DOI 10.1038/nature11378, PubMed 22885699
7. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
   Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
   Leuk Lymphoma, 53 (10), 1934-44
   DOI 10.3109/10428194.2012.682307, PubMed 22475179
8. Zhen Y, Sørensen V, Skjerpen CS, Haugsten EM, Jin Y, Wälchli S, Olsnes S, Wiedlocha A (2012)
   Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1
   Traffic, 13 (5), 650-64
   DOI 10.1111/j.1600-0854.2012.01341.x, PubMed 22321063

Publications 2011

1. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R (2011)
   Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
   Blood, 118 (5), 1350-8
   DOI 10.1182/blood-2011-03-345272, PubMed 21670469
2. Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Grøseth LA, Rekvig M, Børset M, Standal T, Waage A, Sundan A (2011)
   Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC
   Leukemia, 26 (5), 1073-80
   DOI 10.1038/leu.2011.263, PubMed 21941367
3. Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH (2011)
   Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7
   Eur J Immunol, 41 (11), 3135-45
   DOI 10.1002/eji.201141558, PubMed 21898381
4. Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G (2011)
   Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy
   Eur J Haematol, 87 (6), 494-502
   DOI 10.1111/j.1600-0609.2011.01681.x, PubMed 21752097
5. Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA (2011)
   LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome
   Haematologica, 96 (7), 980-6
   DOI 10.3324/haematol.2011.040568, PubMed 21459790
6. Tkacz-Stachowska K, Lund-Andersen C, Velissarou A, Myklebust JH, Stokke T, Syljuåsen RG (2011)
   The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells
   Radiother Oncol, 101 (1), 24-7
   DOI 10.1016/j.radonc.2011.05.060, PubMed 21722983
7. Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
   Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
   Br J Haematol, 156 (2), 225-33
   DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Publications 2010

1. Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP (2010)
   TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK
   BMC Immunol, 11, 57
   DOI 10.1186/1471-2172-11-57, PubMed 21092277
2. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010)
   Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma
   Cell, 142 (5), 699-713
   DOI 10.1016/j.cell.2010.07.044, PubMed 20813259
3. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E et al. (2010)
   Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
   Nature, 463 (7277), 88-92
   DOI 10.1038/nature08638, PubMed 20054396
4. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
   Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
   Blood, 116 (9), 1489-97
   DOI 10.1182/blood-2010-03-272278, PubMed 20505157
5. Groth M, Wiegand C, Szafranski K, Huse K, Kramer M, Rosenstiel P, Schreiber S, Norgauer J, Platzer M (2010)
   Both copy number and sequence variations affect expression of human DEFB4
   Genes Immun, 11 (6), 458-66
   DOI 10.1038/gene.2010.19, PubMed 20445567
6. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R (2010)
   B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
   Proc Natl Acad Sci U S A, 107 (29), 12747-54
   DOI 10.1073/pnas.1002057107, PubMed 20543139
7. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI et al. (2010)
   Oncogenically active MYD88 mutations in human lymphoma
   Nature, 470 (7332), 115-9
   DOI 10.1038/nature09671, PubMed 21179087
8. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM et al. (2010)
   Cooperative epigenetic modulation by cancer amplicon genes
   Cancer Cell, 18 (6), 590-605
   DOI 10.1016/j.ccr.2010.11.013, PubMed 21156283
9. Smeland EB, Vartdal F, Wisløff F (2010)
   [Close cooperation, but not oversteering]
   Tidsskr Nor Laegeforen, 130 (6), 590-1
   DOI 10.4045/tidsskr.10.0153, PubMed 20348990
10. Smeland EB, Vartdal F, Wisløff F (2010)
    [Leadership and academic competence]
    Tidsskr Nor Laegeforen, 130 (6), 591
    DOI 10.4045/tidsskr.10.0217, PubMed 20348994

Publications 2009

1. Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
   [Molecular diagnosis of malignant lymphomas]
   Tidsskr Nor Laegeforen, 129 (22), 2352-6
   DOI 10.4045/tidsskr.09.0704, PubMed 19935935
2. Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R (2009)
   Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
   Blood, 114 (16), 3431-8
   DOI 10.1182/blood-2009-05-223958, PubMed 19641184
3. Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A (2009)
   c-Met signaling promotes IL-6-induced myeloma cell proliferation
   Eur J Haematol, 82 (4), 277-87
   DOI 10.1111/j.1600-0609.2009.01212.x, PubMed 19187270
4. O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM et al. (2009)
   Array-based DNA methylation profiling in follicular lymphoma
   Leukemia, 23 (10), 1858-66
   DOI 10.1038/leu.2009.114, PubMed 19587707

Publications 2008

1. Døsen-Dahl G, Munthe E, Nygren MK, Stubberud H, Hystad ME, Rian E (2008)
   Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: role of TGFbeta/BMP-6 and TIEG1 in chemotherapy escape
   Int J Cancer, 123 (12), 2759-66
   DOI 10.1002/ijc.23833, PubMed 18798273
2. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM (2008)
   Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
   Science, 319 (5870), 1676-9
   DOI 10.1126/science.1153629, PubMed 18323416
3. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G et al. (2008)
   Stromal gene signatures in large-B-cell lymphomas
   N Engl J Med, 359 (22), 2313-23
   DOI 10.1056/NEJMoa0802885, PubMed 19038878
4. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM (2008)
   Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
   Proc Natl Acad Sci U S A, 105 (36), 13520-5
   DOI 10.1073/pnas.0804295105, PubMed 18765795
5. O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J (2008)
   The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
   Blood, 112 (8), 3126-9
   DOI 10.1182/blood-2008-05-154013, PubMed 18628487

Publications 2007

1. Cabezón T, Celis JE, Skibshøj I, Klingelhöfer J, Grigorian M, Gromov P, Rank F, Myklebust JH, Maelandsmo GM, Lukanidin E, Ambartsumian N (2007)
   Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer
   Int J Cancer, 121 (7), 1433-44
   DOI 10.1002/ijc.22850, PubMed 17565747
2. Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
   Characterization of early stages of human B cell development by gene expression profiling
   J Immunol, 179 (6), 3662-71
   DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802
3. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM (2007)
   Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma
   J Exp Med, 204 (3), 633-43
   DOI 10.1084/jem.20062041, PubMed 17353367
4. Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
   Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
   Eur J Immunol, 37 (10), 2937-48
   DOI 10.1002/eji.200636759, PubMed 17899540
5. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI et al. (2007)
   Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
   Blood, 109 (11), 4599-606
   DOI 10.1182/blood-2006-08-039859, PubMed 17299095
6. Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S (2007)
   Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations
   J Cancer Res Clin Oncol, 133 (7), 455-70
   DOI 10.1007/s00432-006-0188-3, PubMed 17235551

Publications 2006

1. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB et al. (2006)
   Molecular diagnosis of Burkitt's lymphoma
   N Engl J Med, 354 (23), 2431-42
   DOI 10.1056/NEJMoa055759, PubMed 16760443
2. Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
   BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
   Exp Hematol, 34 (1), 72-81
   DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393
3. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E (2006)
   Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines
   Br J Haematol, 136 (3), 400-13
   DOI 10.1111/j.1365-2141.2006.06442.x, PubMed 17156404
4. Sioud M, Fløisand Y, Forfang L, Lund-Johansen F (2006)
   Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage
   J Mol Biol, 364 (5), 945-54
   DOI 10.1016/j.jmb.2006.09.054, PubMed 17049554
5. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
   Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
   Leukemia, 20 (3), 539-42
   DOI 10.1038/sj.leu.2404094, PubMed 16437153
6. Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH (2006)
   PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells
   Br J Haematol, 135 (1), 117-28
   DOI 10.1111/j.1365-2141.2006.06252.x, PubMed 16965383
7. Winning J, Claus RA, Huse K, Bauer M (2006)
   Molecular biology on the ICU. From understanding to treating sepsis
   Minerva Anestesiol, 72 (5), 255-67
   PubMed 16675935
8. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N, Zeitlmann L, Grosse J, Ruf N, Nürnberg P, Costello CM, Onnie C, Mathew C, Platzer M, Schreiber S, Hampe J (2006)
   Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease
   Genes Immun, 7 (1), 11-8
   DOI 10.1038/sj.gene.6364263, PubMed 16222343

Publications 2005

1. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R et al. (2005)
   Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
   Blood, 106 (9), 3183-90
   DOI 10.1182/blood-2005-04-1399, PubMed 16046532
2. Galteland E, Sivertsen EA, Svendsrud DH, Smedshammer L, Kresse SH, Meza-Zepeda LA, Myklebost O, Suo Z, Mu D, Deangelis PM, Stokke T (2005)
   Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas
   Leukemia, 19 (12), 2313-23
   DOI 10.1038/sj.leu.2403954, PubMed 16193090
3. Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
   BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
   BMC Immunol, 6, 9
   DOI 10.1186/1471-2172-6-9, PubMed 15877825
4. Moche M, Hui DS, Huse K, Chan KS, Choy DK, Scholz GH, Gosse H, Winkler J, Schauer J, Sack U, Hoheisel G (2005)
   [Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion]
   Pneumologie, 59 (8), 523-8
   DOI 10.1055/s-2005-870966, PubMed 16110415
5. Patzke S, Hauge H, Sioud M, Finne EF, Sivertsen EA, Delabie J, Stokke T, Aasheim HC (2005)
   Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization
   Oncogene, 24 (7), 1159-73
   DOI 10.1038/sj.onc.1208267, PubMed 15580290
6. Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
   PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
   J Pathol, 206 (3), 312-9
   DOI 10.1002/path.1777, PubMed 15892171

Publications 2004

1. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA et al. (2004)
   Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
   N Engl J Med, 351 (21), 2159-69
   DOI 10.1056/NEJMoa041869, PubMed 15548776
2. Fosså A, Alsøe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004)
   Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display
   Cancer Immunol Immunother, 53 (5), 431-8
   DOI 10.1007/s00262-003-0458-8, PubMed 14747957
3. Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB (2004)
   NY-ESO-1 protein expression and humoral immune responses in prostate cancer
   Prostate, 59 (4), 440-7
   DOI 10.1002/pros.20025, PubMed 15065093
4. Holm AM, Sivertsen EA, Tunheim SH, Haug T, Bjerkeli V, Yndestad A, Aukrust P, Frøland SS (2004)
   Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells
   Clin Exp Immunol, 138 (2), 278-89
   DOI 10.1111/j.1365-2249.2004.02630.x, PubMed 15498038
5. Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
   Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
   Cancer Immunol Immunother, 53 (12), 1119-26
   DOI 10.1007/s00262-004-0558-0, PubMed 15185015
6. Moe JF, Sivertsen E, van Thanh D (2004)
   Adapting email functionality for mobile terminals
   LECT NOTES COMPUT SC, 3283, 199-206
7. Sinnreich O, Kratzsch J, Reichenbach A, Gläser C, Huse K, Birkenmeier G (2004)
   Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters
   Prostate, 61 (3), 201-8
   DOI 10.1002/pros.20062, PubMed 15368477

Publications 2003

1. Birkenmeier G, Müller R, Huse K, Forberg J, Gläser C, Hedrich H, Nicklisch S, Reichenbach A (2003)
   Human alpha2-macroglobulin: genotype-phenotype relation
   Exp Neurol, 184 (1), 153-61
   DOI 10.1016/s0014-4886(03)00110-9, PubMed 14637088
2. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R et al. (2003)
   Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
   J Exp Med, 198 (6), 851-62
   DOI 10.1084/jem.20031074, PubMed 12975453
3. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC et al. (2003)
   The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
   Cancer Cell, 3 (2), 185-97
   DOI 10.1016/s1535-6108(03)00028-x, PubMed 12620412

Publications 2002

1. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB (2002)
   Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells
   Exp Hematol, 30 (9), 990-1000
   DOI 10.1016/s0301-472x(02)00868-8, PubMed 12225790
2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
   The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
   N Engl J Med, 346 (25), 1937-47
   DOI 10.1056/NEJMoa012914, PubMed 12075054
3. Wang J, Delabie J, Aasheim H, Smeland E, Myklebost O (2002)
   Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study
   BMC Bioinformatics, 3, 36
   DOI 10.1186/1471-2105-3-36, PubMed 12445336

Publications 2001

1. Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
   High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
   Bone Marrow Transplant, 28 (9), 849-57
   DOI 10.1038/sj.bmt.1703244, PubMed 11781645
2. Hoheisel G, Sack U, Hui DS, Huse K, Chan KS, Chan KK, Hartwig K, Schuster E, Scholz GH, Schauer J (2001)
   Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis
   Tuberculosis (Edinb), 81 (3), 203-9
   DOI 10.1054/tube.2000.0276, PubMed 11466032
3. Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
   [Gene therapy in cancer]
   Tidsskr Nor Laegeforen, 121 (4), 482-8
   PubMed 11255868
4. Lyngstadaas A, Smeland EB (2001)
   [Gene therapy--status and recommendations in Norwegian health care system]
   Tidsskr Nor Laegeforen, 121 (3), 343-8
   PubMed 11242880
5. Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB, Delabie J, Holte H (2001)
   Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
   Br J Cancer, 85 (12), 1900-13
   DOI 10.1054/bjoc.2001.2164, PubMed 11747333

Publications 2000

1. Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
   Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
   Br J Cancer, 83 (6), 743-9
   DOI 10.1054/bjoc.2000.1365, PubMed 10952778
2. Josefsen D, Myklebust JH, Lømo J, Sioud M, Blomhoff HK, Smeland EB (2000)
   Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells
   Stem Cells, 18 (4), 261-72
   DOI 10.1634/stemcells.18-4-261, PubMed 10924092
3. Myklebust JH, Smeland EB, Josefsen D, Sioud M (2000)
   Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow
   Blood, 95 (2), 510-8
   DOI 10.1182/blood.V95.2.510, PubMed 10627456
4. Naderi S, Gützkow KB, Christoffersen J, Smeland EB, Blomhoff HK (2000)
   cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of cyclin D3 at the level of translation
   Eur J Immunol, 30 (6), 1757-68
   DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N, PubMed 10898514
5. Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB (2000)
   Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
   Int J Cancer, 89 (4), 313-24
   DOI 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>3.0.co;2-d, PubMed 10956404
6. Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T (2000)
   A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes
   Blood, 95 (1), 221-30
   DOI 10.1182/blood.V95.1.221.001k01_221_230, PubMed 10607706

Publications 1999

1. Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E (1999)
   Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction
   Diagn Mol Pathol, 8 (4), 183-8
   DOI 10.1097/00019606-199912000-00003, PubMed 10617274
2. Fosså A, Brandhorst D, Myklebust JH, Seeber S, Nowrousian MR (1999)
   Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma
   Exp Hematol, 27 (11), 1621-6
   DOI 10.1016/s0301-472x(99)00105-8, PubMed 10560909
3. Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
   Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
   Acta Oncol, 38 (4), 495-503
   DOI 10.1080/028418699432040, PubMed 10418718
4. Josefsen D, Blomhoff HK, Lømo J, Blystad AK, Smeland EB (1999)
   Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells
   Exp Hematol, 27 (4), 642-53
   DOI 10.1016/s0301-472x(98)00073-3, PubMed 10210322
5. Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB (1999)
   Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis
   Exp Hematol, 27 (9), 1451-9
   DOI 10.1016/s0301-472x(99)00073-9, PubMed 10480436
6. Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC, Smeland EB (1999)
   Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression
   J Cell Physiol, 180 (1), 71-80
   DOI 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N, PubMed 10362019
7. Naderi S, Blomhoff R, Myklebust J, Smeland EB, Erikstein B, Norum KR, Blomhoff HK (1999)
   Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis
   Exp Cell Res, 252 (1), 144-53
   DOI 10.1006/excr.1999.4608, PubMed 10502407
8. Smeland E (1999)
   [University function at the central hospital in Akershus]
   Tidsskr Nor Laegeforen, 119 (11), 1647
   PubMed 10385812

Publications 1998

1. Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
   Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
   Bone Marrow Transplant, 21 (9), 873-8
   DOI 10.1038/sj.bmt.1701192, PubMed 9613778
2. Heim S, Smeland EB (1998)
   [Molecular genetic diagnosis of leukemias and lymphomas]
   Tidsskr Nor Laegeforen, 118 (16), 2511-8
   PubMed 9667131
3. Ly B, Hammerstrøm J, Bergheim J, Dahl IM, Grøttum KA, Lødemel B, Baklien K, Smeland E (1998)
   [Chronic lymphatic leukemia. Immunophenotyping as an aid to correct diagnosis]
   Tidsskr Nor Laegeforen, 118 (2), 233-7
   PubMed 9485618
4. Lømo J, Smeland EB, Ulven S, Natarajan V, Blomhoff R, Gandhi U, Dawson MI, Blomhoff HK (1998)
   RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes
   J Cell Physiol, 175 (1), 68-77
   DOI 10.1002/(SICI)1097-4652(199804)175:1<68::AID-JCP8>3.0.CO;2-A, PubMed 9491782
5. Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G (1998)
   Generation and characterization of gp100 peptide-specific NK-T cell clones
   Int J Cancer, 75 (5), 794-803
   DOI 10.1002/(sici)1097-0215(19980302)75:5<794::aid-ijc21>3.0.co;2-5, PubMed 9495251
6. Scholz GH, Vieweg S, Leistner S, Seissler J, Scherbaum WA, Huse K (1998)
   A simplified procedure for the isolation of immunoglobulins from human serum using a novel type of thiophilic gel at low salt concentration
   J Immunol Methods, 219 (1-2), 109-18
   DOI 10.1016/s0022-1759(98)00132-x, PubMed 9831392
7. Scholz GH, Wippich P, Leistner S, Huse K (1998)
   Salt-independent binding of antibodies from human serum to thiophilic heterocyclic ligands
   J Chromatogr B Biomed Sci Appl, 709 (2), 189-96
   DOI 10.1016/s0378-4347(98)00109-1, PubMed 9657215
8. Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB (1998)
   Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1832-8
   DOI 10.1038/bjc.1998.304, PubMed 9667654
9. Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
   Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
   Br J Cancer, 77 (11), 1839-41
   DOI 10.1038/bjc.1998.305, PubMed 9667655

Publications 1997

1. Hallan E, Blomhoff HK, Smeland EB, Lømo J (1997)
   Involvement of ICE (Caspase) family in gamma-radiation-induced apoptosis of normal B lymphocytes
   Scand J Immunol, 46 (6), 601-8
   DOI 10.1046/j.1365-3083.1997.d01-173.x, PubMed 9420624
2. Kvingedal AM, Smeland EB (1997)
   A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue
   FEBS Lett, 407 (1), 59-62
   DOI 10.1016/s0014-5793(97)00278-0, PubMed 9141481
3. Lømo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB (1997)
   Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1
   Blood, 89 (12), 4415-24
   PubMed 9192766
4. Rasmussen AM, Horejsí V, Levy FO, Blomhoff HK, Smeland EB, Beiske K, Michaelsen TE, Gaudernack G, Funderud S (1997)
   CDw78--a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton
   Eur J Immunol, 27 (12), 3206-13
   DOI 10.1002/eji.1830271218, PubMed 9464807
5. Smeland E (1997)
   [Changing physician's role]
   Tidsskr Nor Laegeforen, 117 (29), 4290
   PubMed 9441481
6. Aasheim HC, Pedeutour F, Smeland EB (1997)
   Characterization, expression and chromosomal localization of a human gene homologous to the mouse Lsc oncogene, with strongest expression in hematopoetic tissues
   Oncogene, 14 (14), 1747-52
   DOI 10.1038/sj.onc.1200994, PubMed 9135076

Publications 1996

1. Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
   [High-dose therapy of cancer with CD34 positive cells as stem cell support]
   Tidsskr Nor Laegeforen, 116 (21), 2542-6
   PubMed 8928121
2. Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
   Purging of tumor cells from leukapheresis products: experimental and clinical aspects
   J Hematother, 5 (4), 427-36
   DOI 10.1089/scd.1.1996.5.427, PubMed 8877718
3. Levy FO, Rasmussen AM, Taskén K, Skålhegg BS, Huitfeldt HS, Funderud S, Smeland EB, Hansson V (1996)
   Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation
   Eur J Immunol, 26 (6), 1290-6
   DOI 10.1002/eji.1830260617, PubMed 8647207
4. Lømo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK (1996)
   Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
   Cancer Res, 56 (1), 40-3
   PubMed 8548771
5. Rusten LS, Dybedal I, Blomhoff HK, Blomhoff R, Smeland EB, Jacobsen SE (1996)
   The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells
   Blood, 87 (5), 1728-36
   PubMed 8634418
6. Røsok O, Odeberg J, Rode M, Stokke T, Funderud S, Smeland E, Lundeberg J (1996)
   Solid-phase method for differential display of genes expressed in hematopoietic stem cells
   Biotechniques, 21 (1), 114-21
   DOI 10.2144/96211rr02, PubMed 8816245
7. Schneider H, Huse K (1996)
   Arterial gene therapy
   Lancet, 348 (9038), 1380-1; author reply 1381-2
   DOI 10.1016/S0140-6736(05)65442-6, PubMed 8918290
8. Schneider H, Huse K, Birkenmeier G, Otto A, Scholz GH (1996)
   Gene transfer mediated by alpha2-macroglobulin
   Nucleic Acids Res, 24 (19), 3873-4
   DOI 10.1093/nar/24.19.3873, PubMed 8871570

Publications 1995

1. Deggerdal AH, Pettersen F, Kvalheim G, Hornes E, Smeland E, Fodstad O, Hovig E (1995)
   Semiquantitative polymerase chain reaction for t(14;18) in follicular lymphomas: a colorimetric approach
   Lab Invest, 72 (4), 411-8
   PubMed 7723279
2. Fahlman C, Jacobsen SE, Smeland EB, Lømo J, Naess CE, Funderud S, Blomhoff HK (1995)
   All-trans- and 9-cis-retinoic acid inhibit growth of normal human and murine B cell precursors
   J Immunol, 155 (1), 58-65
   PubMed 7602122
3. Lømo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB (1995)
   TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
   J Immunol, 154 (4), 1634-43
   PubMed 7836748
4. Smeland E (1995)
   [Physicians liable for military service for sale]
   Tidsskr Nor Laegeforen, 115 (24), 3072
   PubMed 7570542
5. Aas-Eng DA, Asheim HC, Deggerdal A, Smeland E, Funderud S (1995)
   Characterization of a promoter region supporting transcription of a novel human beta-galactoside alpha-2,6-sialyltransferase transcript in HepG2 cells
   Biochim Biophys Acta, 1261 (1), 166-9
   DOI 10.1016/0167-4781(94)00250-7, PubMed 7893756

Publications 1994

1. Christoffersen J, Smeland EB, Stokke T, Taskén K, Andersson KB, Blomhoff HK (1994)
   Retinoblastoma protein is rapidly dephosphorylated by elevated cyclic adenosine monophosphate levels in human B-lymphoid cells
   Cancer Res, 54 (8), 2245-50
   PubMed 8174134
2. Jacobsen FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slørdal L, Jacobsen SE (1994)
   Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis
   Proc Natl Acad Sci U S A, 91 (22), 10695-9
   DOI 10.1073/pnas.91.22.10695, PubMed 7524102
3. Jacobsen SE, Fahlman C, Blomhoff HK, Okkenhaug C, Rusten LS, Smeland EB (1994)
   All-trans- and 9-cis-retinoic acid: potent direct inhibitors of primitive murine hematopoietic progenitors in vitro
   J Exp Med, 179 (5), 1665-70
   DOI 10.1084/jem.179.5.1665, PubMed 8163945
4. Kvalheim G, Jakobsen E, Holte H, Beiske K, Langholm R, Høiby A, Wang MY, Funderund S, Fodstad O, Smeland E (1994)
   Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged using immunomagnetic beads
   Prog Clin Biol Res, 389, 133-8
   PubMed 7700895
5. Kvaløy SO, Smeland EB (1994)
   [Bone marrow transplantation--a constantly developing procedure--requiring updating]
   Tidsskr Nor Laegeforen, 114 (3), 302-3
   PubMed 8191422
6. Rasmussen AM, Blomhoff HK, Stokke T, Horejsi V, Smeland EB (1994)
   Cross-linking of CD53 promotes activation of resting human B lymphocytes
   J Immunol, 153 (11), 4997-5007
   PubMed 7963560
7. Rusten LS, Jacobsen FW, Lesslauer W, Loetscher H, Smeland EB, Jacobsen SE (1994)
   Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: involvement of p55 and p75 TNF receptors
   Blood, 83 (11), 3152-9
   PubMed 7514902
8. Rusten LS, Jacobsen SE, Kaalhus O, Veiby OP, Funderud S, Smeland EB (1994)
   Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells
   Blood, 84 (5), 1473-81
   PubMed 7520773
9. Rusten LS, Smeland EB, Jacobsen FW, Lien E, Lesslauer W, Loetscher H, Dubois CM, Jacobsen SE (1994)
   Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors
   J Clin Invest, 94 (1), 165-72
   DOI 10.1172/JCI117303, PubMed 7518828
10. Smeland EB, Rusten L, Jacobsen SE, Skrede B, Blomhoff R, Wang MY, Funderud S, Kvalheim G, Blomhoff HK (1994)
    All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells
    Blood, 84 (9), 2940-5
    DOI 10.1182/blood.V84.9.2940.bloodjournal8492940, PubMed 7524761
11. Aasheim HC, Deggerdal A, Smeland EB, Hornes E (1994)
    A simple subtraction method for the isolation of cell-specific genes using magnetic monodisperse polymer particles
    Biotechniques, 16 (4), 716-21
    PubMed 8024795
12. Aasheim HC, Loukianova T, Deggerdal A, Smeland EB (1994)
    Tissue specific expression and cDNA structure of a human transcript encoding a nucleic acid binding [oligo(dC)] protein related to the pre-mRNA binding protein K
    Nucleic Acids Res, 22 (6), 959-64
    DOI 10.1093/nar/22.6.959, PubMed 8152927

Publications 1993

1. Andersson KB, Deggerdal A, Skjønsberg C, Smeland EB, Blomhoff HK (1993)
   Constitutive expression of c-myc does not relieve cAMP-mediated growth arrest in human lymphoid Reh cells
   J Cell Physiol, 157 (1), 61-9
   DOI 10.1002/jcp.1041570108, PubMed 8408242
2. Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
   Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
   Br J Haematol, 83 (3), 392-8
   DOI 10.1111/j.1365-2141.1993.tb04662.x, PubMed 8097923
3. Jacobsen SE, Veiby OP, Smeland EB (1993)
   Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells
   J Exp Med, 178 (2), 413-8
   DOI 10.1084/jem.178.2.413, PubMed 7688022
4. Slørdahl SH, Smeland EB, Holte H, Grønn M, Lie SO, Seip M (1993)
   Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia")
   Med Pediatr Oncol, 21 (4), 254-8
   DOI 10.1002/mpo.2950210404, PubMed 8469219
5. Aasheim HC, Aas-Eng DA, Deggerdal A, Blomhoff HK, Funderud S, Smeland EB (1993)
   Cell-specific expression of human beta-galactoside alpha 2,6-sialyltransferase transcripts differing in the 5' untranslated region
   Eur J Biochem, 213 (1), 467-75
   DOI 10.1111/j.1432-1033.1993.tb17783.x, PubMed 8477718

Publications 1992

1. Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjønsberg C, Blomhoff R (1992)
   Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells
   J Biol Chem, 267 (33), 23988-92
   PubMed 1429735
2. Erikstein BK, Funderud S, Beiske K, Aas-Eng A, De Lange Davies C, Blomhoff HK, Smeland EB (1992)
   Cell cycle-dependent regulation of CDw75 (beta-galactoside alpha-2,6-sialyltransferase) on human B lymphocytes
   Eur J Immunol, 22 (5), 1149-55
   DOI 10.1002/eji.1830220507, PubMed 1577059
3. Hohmann S, Huse K, Valentin E, Mbonyi K, Thevelein JM, Zimmermann FK (1992)
   Glucose-induced regulatory defects in the Saccharomyces cerevisiae byp1 growth initiation mutant and identification of MIG1 as a partial suppressor
   J Bacteriol, 174 (12), 4183-8
   DOI 10.1128/jb.174.12.4183-4188.1992, PubMed 1597433
4. Rasmussen AM, Smeland EB, Erikstein BK, Caignault L, Funderud S (1992)
   A new method for detachment of Dynabeads from positively selected B lymphocytes
   J Immunol Methods, 146 (2), 195-202
   DOI 10.1016/0022-1759(92)90228-l, PubMed 1371532
5. Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T (1992)
   Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells
   Leukemia, 6 (8), 845-52
   PubMed 1379314
6. Stokke T, Holte H, Smeland EB, Lie SO, Steen HB (1992)
   Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells
   Cancer Res, 52 (18), 5007-12
   PubMed 1516056

Publications 1991

1. Bremnes RM, Smeland E, Huseby NE, Eide TJ, Aarbakke J (1991)
   Acute hepatotoxicity after high-dose methotrexate administration to rats
   Pharmacol Toxicol, 69 (2), 132-9
   DOI 10.1111/j.1600-0773.1991.tb01286.x, PubMed 1775433
2. Bremnes RM, Smeland E, Slørdal L, Wist E, Aarbakke J (1991)
   The effect of vindesine on methotrexate hydroxylation in the rat
   Biochem Pharmacol, 42 (8), 1561-8
   DOI 10.1016/0006-2952(91)90425-5, PubMed 1930283
3. Bremnes RM, Smeland E, Willassen NP, Wist E, Aarbakke J (1991)
   Inhibition of 7-hydroxymethotrexate formation by amsacrine
   Cancer Chemother Pharmacol, 28 (5), 377-83
   DOI 10.1007/BF00685693, PubMed 1914082
4. Erikstein BK, Schwarze P, Blomhoff HK, Funderud S, Stokke T, Smeland EB (1991)
   Use of size fractionation of in vitro-activated human B lymphocytes for studies of cell cycle-dependent growth regulation
   Scand J Immunol, 33 (1), 51-60
   DOI 10.1111/j.1365-3083.1991.tb02491.x, PubMed 1899949
5. Erikstein BK, Smeland EB, Blomhoff HK, Funderud S, Prydz K, Lesslauer W, Espevik T (1991)
   Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes
   Eur J Immunol, 21 (4), 1033-7
   DOI 10.1002/eji.1830210426, PubMed 1850359
6. Lømo J, Smeland EB, Stokke T, Holte H, Funderud S, Blomhoff HK (1991)
   Differential effects of interferon-gamma and low molecular weight BCGF on growth of human B lymphocytes; interferon-gamma prolongs the increased c-MYC mRNA levels after activation
   Scand J Immunol, 33 (4), 365-73
   DOI 10.1111/j.1365-3083.1991.tb01783.x, PubMed 1902001
7. Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T (1991)
   Immunomagnetic isolation of NK and LAK cells
   J Immunol Methods, 136 (1), 1-9
   DOI 10.1016/0022-1759(91)90242-8, PubMed 1704900
8. Skjønsberg C, Erikstein BK, Smeland EB, Lie SO, Funderud S, Beiske K, Blomhoff HK (1991)
   Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias
   Blood, 77 (11), 2445-50
   PubMed 2039826
9. Skrede B, Blomhoff HK, Smeland EB, Wathne KO, Norum KR, Blomhoff R (1991)
   Retinyl esters in chylomicron remnants inhibit growth of myeloid and lymphoid leukaemic cells
   Eur J Clin Invest, 21 (6), 574-9
   DOI 10.1111/j.1365-2362.1991.tb01411.x, PubMed 1778218

Publications 1990

1. Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB (1990)
   Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation
   Eur J Immunol, 20 (1), 201-6
   DOI 10.1002/eji.1830200129, PubMed 1689662
2. Helgestad J, Pettersen R, Storm-Mathisen I, Schjerven L, Ulrich K, Smeland EB, Egeland T, Sørskaard D, Brøgger A, Hovig T (1990)
   Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid
   Eur J Haematol, 44 (1), 9-17
   DOI 10.1111/j.1600-0609.1990.tb00340.x, PubMed 2307225
3. Schøyen H, Iversen JG, Smeland EB, Heikkilä R (1990)
   A transient acidification linked to intracellular Ca2+ in anti-mu-stimulated human B-lymphocytes
   Acta Physiol Scand, 138 (2), 221-7
   DOI 10.1111/j.1748-1716.1990.tb08836.x, PubMed 1690498
4. Skjønsberg C, Kiil Blomhoff H, Gaudernack G, Funderud S, Beiske K, Smeland EB (1990)
   Immunological typing of acute leukaemias by rosetting with immunomagnetic beads: comparison with immunofluorescence staining
   Scand J Immunol, 31 (5), 567-73
   DOI 10.1111/j.1365-3083.1990.tb02807.x, PubMed 2189214
5. Stamenkovic I, Asheim HC, Deggerdal A, Blomhoff HK, Smeland EB, Funderud S (1990)
   The B cell antigen CD75 is a cell surface sialytransferase
   J Exp Med, 172 (2), 641-3
   DOI 10.1084/jem.172.2.641, PubMed 2373995

Publications 1989

1. Brinch L, Evensen SA, Stavem P, Smeland EB (1989)
   [Experiences of immunologic phenotyping in acute leukemia]
   Tidsskr Nor Laegeforen, 109 (4), 443-6
   PubMed 2919374
2. Børresen AL, Brøgger A, Møller P, Smeland E (1989)
   [Gene technology in the prevention of cancer]
   Tidsskr Nor Laegeforen, 109 (33), 3430-4
   PubMed 2609305
3. Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
   Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
   Eur J Immunol, 19 (7), 1221-5
   DOI 10.1002/eji.1830190711, PubMed 2547623
4. Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
   Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
   Int J Cancer, 44 (6), 975-80
   DOI 10.1002/ijc.2910440605, PubMed 2606582
5. Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R (1989)
   Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas
   Int J Cancer, 43 (1), 164-70
   DOI 10.1002/ijc.2910430130, PubMed 2642893
6. Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T (1989)
   Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes
   J Exp Med, 170 (4), 1463-8
   DOI 10.1084/jem.170.4.1463, PubMed 2677211
7. Smeland EB, Godal T (1989)
   [The 1989 Nobel Prize in physiology and medicine]
   Tidsskr Nor Laegeforen, 109 (34-36), 3541-2
   PubMed 2694425

Publications 1988

1. Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T (1988)
   Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets
   Int J Cancer, 42 (4), 521-8
   DOI 10.1002/ijc.2910420409, PubMed 2459071
2. Blomhoff HK, Blomhoff R, Stokke T, deLange Davies C, Brevik K, Smeland EB, Funderud S, Godal T (1988)
   cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1
   J Cell Physiol, 137 (3), 583-7
   DOI 10.1002/jcp.1041370327, PubMed 2848044
3. Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB (1988)
   Cyclic AMP has the ability to influence multiple events during B cell stimulation
   Eur J Immunol, 18 (9), 1359-66
   DOI 10.1002/eji.1830180909, PubMed 2458941
4. Kriegel T, Huse K, Kopperschläger G (1988)
   The use of separated subunits of yeast phosphofructokinase for the isolation of subunit-specific antibodies from polyclonal antisera
   Biomed Biochim Acta, 47 (7), 705-11
   PubMed 2974282
5. Smeland EB (1988)
   [The immunoglobulin gene superfamily]
   Tidsskr Nor Laegeforen, 108 (13), 1029-32, 1004
   PubMed 2455362
6. Smeland EB (1988)
   [Cellular oncogenes. Role in normal cell growth and activation in neoplasms]
   Tidsskr Nor Laegeforen, 108 (16), 1299-303
   PubMed 3291192
7. Wathne KO, Norum KR, Smeland E, Blomhoff R (1988)
   Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells
   J Biol Chem, 263 (18), 8691-5
   PubMed 3163997

Publications 1987

1. Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R (1987)
   Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage
   Eur J Immunol, 17 (2), 299-301
   DOI 10.1002/eji.1830170224, PubMed 3030769
2. Blomhoff HK, Smeland EB, Beiske K, Blomhoff R, Ruud E, Bjøro T, Pfeifer-Ohlsson S, Watt R, Funderud S, Godal T (1987)
   Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes
   J Cell Physiol, 131 (3), 426-33
   DOI 10.1002/jcp.1041310315, PubMed 3036888
3. Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
   The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
   Int J Cancer, 39 (5), 590-4
   DOI 10.1002/ijc.2910390508, PubMed 3106247
4. Lømo J, Holte H, de Lange Davies C, Ruud E, Laukas M, Smeland EB, Godal T, Blomhoff HK (1987)
   Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines
   Exp Cell Res, 172 (1), 84-91
   DOI 10.1016/0014-4827(87)90095-4, PubMed 3115797
5. Piek J, Adelt T, Huse K, Bock WJ (1987)
   [Cerebrospinal fluid and plasma aminograms in patients with primary and secondary tumors of the CNS]
   Infusionsther Klin Ernahr, 14 (2), 73-7
   PubMed 3610311
6. Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
   Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
   J Immunol, 138 (10), 3179-84
   PubMed 3553323
7. Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
   Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
   Exp Cell Res, 171 (1), 213-22
   DOI 10.1016/0014-4827(87)90264-3, PubMed 2442015

Publications 1986

1. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O (1986)
   Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study
   Br Med J (Clin Res Ed), 293 (6556), 1195-9
   DOI 10.1136/bmj.293.6556.1195, PubMed 3096429
2. Lea T, Smeland E, Funderud S, Vartdal F, Davies C, Beiske K, Ugelstad J (1986)
   Characterization of human mononuclear cells after positive selection with immunomagnetic particles
   Scand J Immunol, 23 (4), 509-19
   DOI 10.1111/j.1365-3083.1986.tb03083.x, PubMed 2422741
3. Smeland EB, Godal T (1986)
   IgG subclasses in lymphomas
   Monogr Allergy, 19, 164-8
   PubMed 3762542
4. Smeland EB, Godal T, Beiske K, Watt R, Pfeifer-Ohlsson S, Ohlsson R (1986)
   Regulation of c-myc mRNA and protein levels during activation of normal human B cells
   Curr Top Microbiol Immunol, 132, 290-6
   DOI 10.1007/978-3-642-71562-4_43, PubMed 3539537

Publications 1985

1. Andersen HT, Smeland EB, Owe JO, Myhre K (1985)
   Analyses of maximum cardiopulmonary performance during exposure to acute hypoxia at simulated altitude--sea level to 5000 meters (760-404 mm Hg)
   Aviat Space Environ Med, 56 (12), 1192-7
   PubMed 4084174
2. Godal T, Davies C, Smeland EB, Heikkilä R, Funderud S, Steen HB, Hildrum K (1985)
   Antibodies to surface IgM and IgD increase the expression of various class II antigens on human B cells
   Eur J Immunol, 15 (2), 173-7
   DOI 10.1002/eji.1830150212, PubMed 3871699
3. Heikkilä R, Iversen JG, Smeland E, Godal T (1985)
   Intracellular Ca2+ buffering potentiates an 86Rb+ permeability response in human lymphocytes
   Acta Physiol Scand, 124 (2), 247-51
   DOI 10.1111/j.1748-1716.1985.tb07658.x, PubMed 3925725
4. Smeland E, Funderud S, Ruud E, Kiil Blomhoff H, Godal T (1985)
   Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor
   Scand J Immunol, 21 (3), 205-14
   DOI 10.1111/j.1365-3083.1985.tb01422.x, PubMed 3887557
5. Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S, Ohlsson R (1985)
   The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate
   Proc Natl Acad Sci U S A, 82 (18), 6255-9
   DOI 10.1073/pnas.82.18.6255, PubMed 3929253

Publications 1984

1. Bjøro T, Gaarder PI, Smeland EB, Kornstad L (1984)
   Thyroid antibodies in blood donors: prevalence and clinical significance
   Acta Endocrinol (Copenh), 105 (3), 324-9
   DOI 10.1530/acta.0.1050324, PubMed 6702401
2. Porstmann B, Porstmann T, Schmechta H, Nugel E, Huse K, Kopperschläger G, Seifert R (1984)
   Direct two-site binding enzyme immunoassay for human alpha-1-fetoprotein. Part I: Comparison of different peroxidase-IgG-conjugates and various reaction conditions
   Z Med Lab Diagn, 25 (1), 5-13
   PubMed 6202071
3. Smeland EB, Jefferis R, Godal T (1984)
   Surface IgG subclasses in human B cell lymphomas as revealed by monoclonal antibodies
   Clin Exp Immunol, 57 (1), 163-70
   PubMed 6378459
4. Smeland EB, Owe JO, Andersen HT (1984)
   Modification of the 'dividing bradycardia' by hypoxia or exercise
   Respir Physiol, 56 (2), 245-51
   DOI 10.1016/0034-5687(84)90108-7, PubMed 6463431

Publications 1983

1. Huse K, Himmel M, Birkenmeier G, Bohla M, Kopperschläger G (1983)
   A novel purification procedure for human alpha-fetoprotein by application of immobilised Cibacron Blue F3G-A as affinity ligand
   Clin Chim Acta, 133 (3), 335-40
   DOI 10.1016/0009-8981(83)90280-2, PubMed 6194922
2. Huse K, Kopperschläger G (1983)
   Interactions of antibodies against soluble phosphofructokinase with the soluble and particulate enzymes from yeast
   FEBS Lett, 155 (1), 50-4
   DOI 10.1016/0014-5793(83)80207-5, PubMed 6220923

Publications 1982

1. Huse K, Kopperschläger G, Hofmann E (1982)
   A new procedure for the purification of proteinase B from baker's yeast and interaction of the purified enzyme with a specific inhibitor
   Acta Biol Med Ger, 41 (11), 991-1002
   PubMed 6763433

Publications 1981

1. Huse K, Diening G (1981)
   [Anaesthesia and diabetes insipidus. A review (author's transl)]
   Anaesthesist, 30 (4), 159-65
   PubMed 7018319

Publications 1980

1. Huse K, Leem W (1980)
   [Circulatory changes in neurosurgical patients with intracerebral angiomas in neuroleptanaesthesia (author's transl)]
   Anasth Intensivther Notfallmed, 15 (2), 144-51
   PubMed 7396101
2. Huse K, Röhner G (1980)
   [Circulatory effects of dihydrazinophthalazine (Nepresol) compared with sodium nitroprusside in controlled hypotension. A study of neurosurgical patients under neuroleptanesthesia]
   Anasth Intensivther Notfallmed, 15 (2), 152-8
   PubMed 6772047
3. Huse K, Schäffer R, Fistas G (1980)
   [Clinical experiences with diazepam (Valium) - fentanyl combination anesthesia in neurosurgery. A study of circulation and oxygen consumption]
   Anasth Intensivther Notfallmed, 15 (2), 135-43
   PubMed 6772046

Publications 1979

1. Diezel W, Meffert H, Günther W, Huse K, Sönnichsen N (1979)
   [Exacerbation of systemic lupus erythematosus following UV irradiation--a hypothesis]
   Acta Biol Med Ger, 38 (9), 1301-6
   PubMed 399148
2. Huse K, Wiecken H (1979)
   [Circulatory changes in the sitting position during neurosurgical anaesthesia (NLA) (author's transl)]
   Anaesthesist, 28 (12), 557-63
   PubMed 539650

Publications 1978

1. Huse K, Stahl HJ, Krämer M (1978)
   [The effect of buprenorphin on circulation, respiration and the electroencephalogram (a postoperative study of 12 neurosurgical cases) (author's transl)]
   Prakt Anaesth, 13 (6), 489-94
   PubMed 740629

Publications 1977

1. Diezel W, Meffert H, Günther W, Huse K, Sönnichsen N (1977)
   [Exacerbation of lupus erythematodes visceralis due to UV irradiation. Results and hypothetical aspects]
   Dermatol Monatsschr, 163 (4), 290-5
   PubMed 881079

Publications 1976

1. Huse K, Kopperschläger G, Hofmann E (1976)
   Differences in the degradation of yeast phosphofructokinase by proteinases A and B from yeast
   Biochem J, 155 (3), 721-3
   DOI 10.1042/bj1550721, PubMed 133676
2. Wüst HJ, Huse K, Lennartz H (1976)
   [Cardiovascular changes caused by atropine in normo- and hypothermic methoxyflurane anaesthesia (author's transl)]
   Anaesthesist, 25 (9), 418-24
   PubMed 970597

Publications 1974

1. Huse K, Hartung E, Nadjmabadi MH (1974)
   [The effects of naloxone (Narcan) on circulation and respiration after neurolept anaesthesia for neurosurgical operations (author's transl)]
   Anaesthesist, 23 (11), 493-9
   PubMed 4458474
2. Nadjmabadi MH, Huse K (1974)
   [Changes of the pah-plasma levels as a guideline for the renal circulation under the influence of various anaesthetic agents (author's transl)]
   Anaesthesist, 23 (1), 5-9
   PubMed 4458471

Publications 1972

1. Huse K, Nicola E, Jeuken B (1972)
   [Changes of lactic and pyruvic acid levels in the cerebrospinal fluid as possible indicators for central hypoxia. Studies in hydrocephalic children]
   Neurochirurgia (Stuttg), 15 (6), 194-200
   DOI 10.1055/s-0028-1090542, PubMed 4655985
2. Huse K, Röhner G (1972)
   [Hemodynamic changes in methoxyflurane anesthesia with controlled hypotension and hypothermia for neurosurgery]
   Zentralbl Neurochir, 33 (1), 19-33
   PubMed 5072148